Cargando…

Calcipotriol/Betamethasone Dipropionate Aerosol Foam for Plaque Psoriasis: A Prospective, Observational, Non-Interventional, Single-Center Study of Patient Adherence and Satisfaction in Daily Use

BACKGROUND: Psoriasis is a chronic inflammatory disease that has a negative impact on patients’ quality of life. Patients with mild–moderate psoriasis can be treated with topical medications, such as the combination drug calcipotriol/betamethasone dipropionate (Cal/BD). OBJECTIVES: This study invest...

Descripción completa

Detalles Bibliográficos
Autores principales: Navarro-Triviño, Francisco José, Lozano-Lozano, Mario, Ruiz-Villaverde, Ricardo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mattioli 1885 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8172017/
https://www.ncbi.nlm.nih.gov/pubmed/34123560
http://dx.doi.org/10.5826/dpc.1103a56
_version_ 1783702461099278336
author Navarro-Triviño, Francisco José
Lozano-Lozano, Mario
Ruiz-Villaverde, Ricardo
author_facet Navarro-Triviño, Francisco José
Lozano-Lozano, Mario
Ruiz-Villaverde, Ricardo
author_sort Navarro-Triviño, Francisco José
collection PubMed
description BACKGROUND: Psoriasis is a chronic inflammatory disease that has a negative impact on patients’ quality of life. Patients with mild–moderate psoriasis can be treated with topical medications, such as the combination drug calcipotriol/betamethasone dipropionate (Cal/BD). OBJECTIVES: This study investigated the adherence of psoriasis patients to therapy with Cal/BD aerosol foam, as well as their satisfaction with the treatment’s efficacy, safety, and effect on their quality of life. METHODS: Patients with mild–moderate plaque psoriasis were eligible to participate in this open-label, non-placebo controlled, prospective single-center study. Adherence to treatment was assessed using the Morisky-Green scale 4 and 12 weeks after the start of treatment. Satisfaction with the treatment was assessed using the abbreviated Treatment Satisfaction Questionnaire for Medication (TSQM-9). The severity of psoriasis was assessed on the mIGA and PGA scales, and the impact on quality of life was assessed using the PDI and DLQI scales. RESULTS: A total of 65 patients entered the study. Adherence to treatment was good, with 73.8% of patients showing high adherence at 12 weeks. Satisfaction was also good, with 46 patients (70.8%) being completely satisfied. CONCLUSIONS: Over a 4-week period, patients treated with Cal/BD aerosol foam had significant improvement in disease severity that was directly related to treatment adherence.
format Online
Article
Text
id pubmed-8172017
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Mattioli 1885
record_format MEDLINE/PubMed
spelling pubmed-81720172021-06-11 Calcipotriol/Betamethasone Dipropionate Aerosol Foam for Plaque Psoriasis: A Prospective, Observational, Non-Interventional, Single-Center Study of Patient Adherence and Satisfaction in Daily Use Navarro-Triviño, Francisco José Lozano-Lozano, Mario Ruiz-Villaverde, Ricardo Dermatol Pract Concept Research BACKGROUND: Psoriasis is a chronic inflammatory disease that has a negative impact on patients’ quality of life. Patients with mild–moderate psoriasis can be treated with topical medications, such as the combination drug calcipotriol/betamethasone dipropionate (Cal/BD). OBJECTIVES: This study investigated the adherence of psoriasis patients to therapy with Cal/BD aerosol foam, as well as their satisfaction with the treatment’s efficacy, safety, and effect on their quality of life. METHODS: Patients with mild–moderate plaque psoriasis were eligible to participate in this open-label, non-placebo controlled, prospective single-center study. Adherence to treatment was assessed using the Morisky-Green scale 4 and 12 weeks after the start of treatment. Satisfaction with the treatment was assessed using the abbreviated Treatment Satisfaction Questionnaire for Medication (TSQM-9). The severity of psoriasis was assessed on the mIGA and PGA scales, and the impact on quality of life was assessed using the PDI and DLQI scales. RESULTS: A total of 65 patients entered the study. Adherence to treatment was good, with 73.8% of patients showing high adherence at 12 weeks. Satisfaction was also good, with 46 patients (70.8%) being completely satisfied. CONCLUSIONS: Over a 4-week period, patients treated with Cal/BD aerosol foam had significant improvement in disease severity that was directly related to treatment adherence. Mattioli 1885 2021-05-20 /pmc/articles/PMC8172017/ /pubmed/34123560 http://dx.doi.org/10.5826/dpc.1103a56 Text en ©2021 Navarro-Triviño et al. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License BY-NC-4.0, which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original authors and source are credited.
spellingShingle Research
Navarro-Triviño, Francisco José
Lozano-Lozano, Mario
Ruiz-Villaverde, Ricardo
Calcipotriol/Betamethasone Dipropionate Aerosol Foam for Plaque Psoriasis: A Prospective, Observational, Non-Interventional, Single-Center Study of Patient Adherence and Satisfaction in Daily Use
title Calcipotriol/Betamethasone Dipropionate Aerosol Foam for Plaque Psoriasis: A Prospective, Observational, Non-Interventional, Single-Center Study of Patient Adherence and Satisfaction in Daily Use
title_full Calcipotriol/Betamethasone Dipropionate Aerosol Foam for Plaque Psoriasis: A Prospective, Observational, Non-Interventional, Single-Center Study of Patient Adherence and Satisfaction in Daily Use
title_fullStr Calcipotriol/Betamethasone Dipropionate Aerosol Foam for Plaque Psoriasis: A Prospective, Observational, Non-Interventional, Single-Center Study of Patient Adherence and Satisfaction in Daily Use
title_full_unstemmed Calcipotriol/Betamethasone Dipropionate Aerosol Foam for Plaque Psoriasis: A Prospective, Observational, Non-Interventional, Single-Center Study of Patient Adherence and Satisfaction in Daily Use
title_short Calcipotriol/Betamethasone Dipropionate Aerosol Foam for Plaque Psoriasis: A Prospective, Observational, Non-Interventional, Single-Center Study of Patient Adherence and Satisfaction in Daily Use
title_sort calcipotriol/betamethasone dipropionate aerosol foam for plaque psoriasis: a prospective, observational, non-interventional, single-center study of patient adherence and satisfaction in daily use
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8172017/
https://www.ncbi.nlm.nih.gov/pubmed/34123560
http://dx.doi.org/10.5826/dpc.1103a56
work_keys_str_mv AT navarrotrivinofranciscojose calcipotriolbetamethasonedipropionateaerosolfoamforplaquepsoriasisaprospectiveobservationalnoninterventionalsinglecenterstudyofpatientadherenceandsatisfactionindailyuse
AT lozanolozanomario calcipotriolbetamethasonedipropionateaerosolfoamforplaquepsoriasisaprospectiveobservationalnoninterventionalsinglecenterstudyofpatientadherenceandsatisfactionindailyuse
AT ruizvillaverdericardo calcipotriolbetamethasonedipropionateaerosolfoamforplaquepsoriasisaprospectiveobservationalnoninterventionalsinglecenterstudyofpatientadherenceandsatisfactionindailyuse